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  INTRODUCTION 
 Non-steroidal anti-infl  ammatory drugs (NSAIDs) are widely pre-
scribed for the treatment of pain and infl  ammation in patients 
with various musculoskeletal conditions. It is well known that 
NSAIDs induce gastrointestinal (GI) adverse eff  ects,  includ-
ing serious complications such as upper GI bleeding, perfora-
tion, obstruction, and death (  1,2  ). Patients with risk factors are 
more likely to develop serious complications. Risk factors for GI 
complications are well known and depend on patient character-
istics, medical history, and the type of NSAID prescribed (  1,2  ). 
To reduce the risk of these adverse events, diff  erent scientifi  c 
societies and regulatory authorities have developed guidelines 
and recommendations to indicate that patients with risk factors 
should receive preventive treatment including, among others, 
the co-prescription of gastroprotective agents (GPAs), namely a 
standard dose of proton pump inhibitors (PPIs), misoprostol, or 
high-dose famotidine (  3,4  ). 
  Two major challenges to reduce serious GI complications in 
at-risk patients are the low prescription rates of preventive 
therapy and poor patient adherence to prescribed GPAs. Several 
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    METHODS:       This was a prospective, multicenter, observational, longitudinal study. Patients attending 
rheumatology  /  orthopedic clinics who were co-prescribed NSAID plus GPA for at least 15 days and 
had risk factors for GI complications were followed up by telephone call. Optimal adherence was 
deﬁ  ned as taking the drug for   ≥   80 %   of prescribed days. Multivariate logistic regression analysis 
was used to determine factors associated with non-adherence. 
    RESULTS:       Of 1,232 patients interviewed, 192 were excluded because of inaccurate data. Of the remaining 
1,040 patients, 74  %   were prescribed low-dose NSAIDs and 99.8  %   were prescribed a standard or 
high-dose GPA. In all, 70  %   of NSAIDs and 63.1  %   of GPA prescriptions were short term (      <      30 days). 
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events and short-term treatment were independent factors associated with poor adherence for both 
NSAIDs and GPAs. History of uncomplicated peptic ulcer and frequent dosing were additional factors 
associated with non-adherence to NSAIDs. 
    CONCLUSIONS:       Most frequent reasons for non-adherence are infrequent  /  low-intensity rheumatic pain (NSAIDs) or 
forgetfulness (GPAs). Short-term treatment and adverse events were associated with poor adherence 
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studies have reported a lack of correspondence between patterns 
of NSAID and GPA prescription (  5  –  8  ), as well as reduced levels 
of patient adherence to prescribed GPAs, with reported rates of 
non-adherence ranging from 9 to 71  %   (  9  –  11  ). Adherence to GPAs 
below the optimum level (which is defi  ned as taking GPAs for 
  ≥    80  %   of the prescribed days) has been associated with a 2.5- to 
4-fold increase in the risk of upper GI bleeding in patients receiv-
ing  NSAIDs  ( 9 – 11 ). 
  Although these studies have consistently demonstrated reduced 
levels of adherence to GPA therapy among NSAID users, several 
issues remain unresolved. One such issue is that these studies have 
basically evaluated the adherence to PPI therapy of NSAID users 
with varying GI risk levels; however, the actual pattern of NSAID 
prescription in this population and whether patients exhibit diff  er-
ences in adherence to either NSAIDs or GPAs is unclear. Another 
important concern is the reasons for low adherence. Many patients 
take multiple drugs, which may be a factor in cases of poor adher-
ence (  12  ), and patients may elect to take these drugs only if they 
have symptoms. For example, patients may take NSAIDs if they 
have musculoskeletal pain or a PPI if they have dyspepsia, although 
the occurrence of these respective symptoms may not be simul-
taneous. It must be noted that up to 60  %   of patients deve  loping 
upper GI complications have no previous abdominal symptoms 
(  13  ). Based on these considerations, the primary objectives of 
this study were to determine the levels of adherence to prescribed 
GPAs and NSAIDs in at-risk patients. Secondary objectives were 
to describe the type of prescription, and to investigate factors asso-
ciated with adherence.     
  METHODS   
  Settings 
 Th  is was a multicenter, observational, longitudinal study with 
prospective data collection. Th   e study was conducted between 15 
May 2008 and 16 January 2009. Th   ere were a total of 296 doctors 
involved in recruiting patients in 158 diff  erent outpatient clinics 
(mostly rheumatology, traumatology  /  orthopedic or internal 
medicine) distributed throughout Spain.     
  Patients 
  Inclusion criteria were (i) patients attending outpatient clinics 
with a musculoskeletal condition and an indication for NSAID 
prescription; (ii) age   ≥    18 years; (iii) presence of at least one GI 
risk factor of those described below, and (iv) receipt of prescrip-
tions for both an NSAID and a GPA for a minimum of 15 days. 
Th   e only exclusion criterion was treatment with a GPA for reasons 
other than the prevention of NSAID-related complications (e.g., 
gastroesophageal refl  ux disease). All included patients signed an 
informed consent form agreeing to participate in the study. 
  GI risk factors (  3  –  8  ) for this study were (i) age   ≥   60 years; (ii) 
a history of peptic ulcer, ulcer complications, or dyspepsia (a 
marker for increased risk of peptic ulcer, especially in populations 
with high   H. pylori   infection rates (  14  –  17  )); (iii) the use of aspi-
rin, corticosteroids, or anticoagulants in addition to a prescribed 
NSAID; (iv) the use of a high-dose NSAID or the use of two 
NSAIDs. High-dose NSAID, which has been previously defi  ned 
elsewhere (  18,19  ), included treatment with any NSAID at the 
maximum dose recommended for the symptomatic treatment of 
arthritis pain (e.g., diclofenac   ≥  150   mg / day,  aceclofenac   ≥  100   mg /
  day, meloxicam   ≥  15   mg / day,  naproxen   ≥ 1,000   mg / day,  piroxicam 
  ≥  20   mg / day,  and  ibuprofen      >    1,800   mg / day).  Th   e doses of PPI for 
gastroprotection  were  as  follows:  omeprazole  20   mg / day,  lanso-
prazole  30   mg / day,  pantoprazole  20   mg / day,  and  esomeprazole 
20   mg / day.  Among  the  H 2   receptor antagonists, the doses were 
40   mg / 12   h  for  famotidine.  Th   e appropriate doses for misoprostol 
were  200    μ g / 6 – 8   h.   
  Questionnaires and follow-up 
  Investigators enrolled consecutive patients (with the above-
mentioned inclusion criteria and no exclusion criteria) who 
agreed to participate in the study for at least 1 month. Investi-
gators collected data in a closed and pre-printed questionnaire 
that included data concerning demographics (age and sex), GI 
risk factors, and current medication for pre-existing condi-
tions, as well as doses, duration of use, time of use, and reason 
for prescription of NSAID plus GPA. Each questionnaire was 
anonymized, and patients were only identifi  ed by a number. Each 
questionnaire contained a telephone number provided by the 
patient where they could be reached for follow-up. Once com-
pleted, each questionnaire was faxed to the coordinating center 
and the principal investigator (AL) evaluated the consistency 
and completeness of the data provided and requested additional 
information or clarifi  cation, if needed. 
  To be contacted for follow-up, patients signed an informed con-
sent form. Th   ey were also informed that they would receive one or 
two telephone calls from independent researchers who would ask 
questions concerning their disease and the medication they take 
within an investigational project. 
  Patients were followed up with telephone calls at a maximum 
of two diff  erent times. Th  e  fi  rst contact was an early call within 
15 – 18  days  aft  er the medical visit. If the prescription of the 
NSAID plus GPA was for 30       −       60 days or longer, then the patients 
received a second call within a window of 60  ±  7 days. Two inde-
pendent and trained investigators (MPT and PR) carried out the 
calls and completed a structured questionnaire that was origi-
nally validated in a small group of patients to assess the feasi-
bility of the questions. Th  e questions focused on adherence to 
NSAID plus GPA therapy and evaluated levels of adherence and 
reasons for not taking the pills. In general, the call lasted   ~  10     min 
and patients were asked to provide the number of prescriptions 
obtained and the number of pills that remained in the package or 
to be refi  lled at the end of the interview. Th   e study fl  ow is sum-
marized in   Figure 1 .   
  Statistical analysis 
  Descriptive analysis of the patients included demographic and 
clinical characteristics, pharmacological treatments, and frequen-
cies of the main variables of the study (rates of adherence, factors 
associated with adherence and type of prescription). Quantitative 
variables were analyzed using measurements of central tendency © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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(mean and median) and dispersion (95  %   confi  dence intervals 
(CIs), standard deviation, quartiles, and ranges). Qualitative 
variables were defi  ned according to their absolute and relative 
frequencies.  Student ’ s   t  -test was used to analyze quantitative vari-
ables. Categorical variables were analyzed using the     χ    2   test or the 
Fisher  ’  s exact test. Tests were two-tailed with a signifi  cance level 
of 5 % . Multivariate analyses were used to determine risk factors of 
poor adherence to either NSAID or GPA therapy. Optimal adher-
ence was defi  ned as taking GPAs for   ≥  80 %   of  the  prescribed  days. 
Models of logistic regression were constructed based on variables 
of interest (age, gender, ulcer history, concomitant medications 
(including aspirin, corticosteroids, and anticoagulants) history 
of dyspepsia, dose of NSAIDs, use of two NSAIDs, duration 
of treatment, dose timing, number of pills and reasons for not 
taking medication) to provide adjusted odds ratios for each factor. 
A backward selection method was used and those variables with 
a signifi  cance level of        >       0.2 were excluded from the model. 
  Data were analyzed with SAS 8.2 statistical soft  ware (SAS Insti-
tute, Cary, NC). A sample size of 1,200 patients would provide an 
error      <    3 %   for  50 %   levels  of  adherence. 
  An initial analysis of the data on GPA adherence showed an 
unexplainably high proportion of patients who did not provide 
a reason for not starting PPI therapy. Th   is led us to do a manual 
  post hoc   review of the original data collected during the telephone 
call. We found that this proportion was lower, since many of those 
patients had already taken the medication (which was prescribed 
for 2 weeks) at the time of the call, and were incorrectly introduced 
into the database as patients who were not taking the medication 
rather than patients who had fi  nished the prescribed treatment. 
Th   is made us revise the whole database and the questionnaire to 
reconfi  rm that it was the only problem with data entry and the 
interpretation of questions.     
  Ethical considerations 
 Th  is study complied with all ethical considerations involving 
human subjects, as adopted by the 18th World Medical Assem-
bly, Helsinki, Finland. All recorded information was obtained 
following the standard clinical guidelines, and patients were not 
subjected to any therapeutic or diagnostic experimentation. Th  e 
study followed standard security and confi  dentiality measures, 
complying fully with Spanish legislation regarding data protec-
tion (Ley Org  á  nica de 15  /  99). Th   e Regional Ethics Committee for 
Clinical Research, Hospital San Carlos (Madrid) approved this 
study. Th  e patients  ’   names remained confi  dential; identifi  cation 
numbers were used instead.       
  RESULTS   
  Demographics 
  A total of 296 specialists participated in the study and 1,232 
patients agreed to participate, of whom 192 were excluded due 
to incomplete data in the original questionnaire completed by the 
investigator (  n     =    9),  duration  of  treatment      <    15  days  ( n     =    34),  or 
telephone interview not carried out within the pre-specifi  ed time 
window (  n     =    149).  Th   erefore, 1,040 patients were included in the 
fi  nal analysis.   Table 1   presents  patients ’   clinical  characteristics.   
Specialized care center
1.  Enroll patients
2.  Collect data: GI risk factors, 
medication prescribed with 
dose, period, and duration of 
treatment, etc.
Independent coordinating center
First early call
15–18 days after
Data base
Two independent
trained investigators
the medical visit
Second late call
10 min-
Structured
questionnaire
(validated for
feasibility)
60 ± 7 days after
the medical visit
    Figure 1  .                 Study ﬂ  ow. Investigators collected consecutive patients who 
met inclusion and exclusion criteria and who agreed to participate in the 
study. After data collection, the anonymized information was sent to the 
coordinating center. Patients were followed up with telephone calls at two 
different times and the follow-up information was added to the database. 
GI, gastrointestinal.   
    Table 1  .       Demographics of patients and gastrointestinal risk 
factors 
        Variable       Mean (s.d.)       95  %   CI   
      Age (years)    57.1      +      16.0   56.1, 58.1 
      Gender   Female: 722 (69.4  %  )   66.5  %  , 72.2  %   
         Male: 318 (30.6  %  )   27.8  %  , 33.5  %   
        Main risk factors     N   (  %  ) 1,040 (100  %  )       95  %   CI   
           Age   ≥   60 years   522 (50.2  %  )   47.1  %  , 53.3  %   
             History of complicated peptic 
ulcer 
  34 (3.3  %  )   2.3  %  , 4.5  %   
             History of uncomplicated 
peptic ulcer 
  101 (9.7  %  )   8.0  %  , 11.7  %   
           History of dyspepsia    304 (29.2  %  )   26.5  %  , 32.1  %   
             Co-therapy with anticoagulants    47 (4.5  %  )   3.3  %  , 6.0  %   
           Co-therapy with aspirin    82 (7.9  %  )   6.3  %  , 9.7  %   
             Co-therapy with non-aspirin 
antiplatelet agents 
  32 (3.1  %  )   2.1  %  , 4.3  %   
           Treatment with two NSAIDs    77 (7.4  %  )   5.9  %  , 9.2  %   
           High NSAID dose    12 (1.2  %  )   0.6  %  , 2.1  %   
           Other   68 (6.5  %  )   5.1  %  , 8.2  %   
          CI, conﬁ  dence interval; GI, gastrointestinal; NSAIDs, non-steroidal anti-inﬂ  am-
matory drugs.     
          The guidelines of the American College of Gastroenterology consider age to be 
a risk factor when patients are       >      65 years of age. The corresponding ﬁ  gure is 
366  /  1,040 (35.2  %  ). Also, the proportion of patients with very high GI risk 
(patients with a history of complicated ulcer or       >      2 risk factors)= 81  /  1,040 
(7.8  %  ). The total number of patients with one or more GI risk factors 
considering the age cutoff at 65 is 77.3  %  .     The American Journal of GASTROENTEROLOGY  VOLUME 107 | MAY 2012   www.amjgastro.com
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  Type of prescription 
 Th  e most common type of anti-infl  ammatory drug prescribed 
was  traditional  NSAIDs  (862 / 1,040,  82.9 % );  COX-2  selective 
inhibitors represented 13.1  %   (136) of all prescriptions. Among 
traditional NSAIDs, in 682 (79.1  %  ) cases the prescription was 
below the recommended doses. Th  e standard dose was pre-
scribed in 157 (18.2  %  ) cases. In 568 (65.9  %  ) cases, duration of 
treatment  was  short  term  (    <    30  days).  Among  prescriptions  for 
COX-2 selective inhibitors, 31.6  %   were below recommended 
doses, 66.2  %   were for the standard dose, and 61.0  %   were short-
term prescriptions. Th   e majority of prescriptions for traditional 
NSAIDs (81.7  %  ) were either b.i.d. or t.i.d.; by contrast, 89.7  %   of 
COX-2 selective inhibitor prescriptions were to be taken once 
daily. 
  Among patients who were prescribed a GPA, 1,028 (99.4  %  ) 
were also prescribed a PPI, while the remaining patients were pre-
scribed H  2   receptor antagonists (0.39  %  ) or misoprostol (0.19  %  ). 
Th   e doses of PPI prescribed were the approved dose for the indi-
cation of GI prevention of NSAID damage in 70.6  %   of cases, 
while 28  %   of patients were prescribed higher doses. PPI prescrip-
tion was once daily in 95.6  %   of cases. Prescribed PPI treatment 
was short term (       <       30 days) in 63.1  %   of cases; 512 (49.2  %  ) patients 
were additionally taking other types of medication (diff  erent from 
NSAIDs or GPAs) for diff  erent reasons.     
  Adherence to treatment 
 Th   e telephone interview was conducted with the patient in 92.4  %   
of cases. In the remaining 7.6  %   of cases, a family member of the 
patient was also involved in the interview.     
  NSAIDs 
 In 92.5 %  (962 / 1,040) of cases, the patient reported starting NSAID 
treatment. Among 77 patients (1 case with data missing) who did 
not start the prescribed NSAID, the main reasons for not initi-
ating treatment were quite diverse: not properly understanding 
the doctor  ’  s instructions was the most frequently cited reason (24 
[35.8  %  ]), followed by infrequent  /  low-intensity pain (16 [23.9  %  ]), 
fear of adverse events (11 [16.4  %  ]) and taking medications other 
than those prescribed for pain (13 [19.4  %  ]). 
  Of the patients who did initiate therapy, 233 (24.2  %  ) failed to 
take the prescribed NSAID at some point for a mean of 12.2  ±  19.1 
days.  Table 2  summarizes the reasons given by patients for not tak-
ing the prescribed NSAID at some point during treatment which 
were infrequent  /  low-intensity pain (29.4  %  ), development of 
adverse events (15.7  %  ), that the prescribed NSAID was ineff  ective 
(9.3  %  ), forgetfulness (12.5  %  ), and not getting a second prescrip-
tion (31.4  %  ). 
 Th   e  majority  of  patients  (79.7 % ;  95 %   CI:  76.9    −    82.2 % )  exhibited 
optimal adherence, taking the prescribed NSAID for 80  %   or more 
of the days prescribed.     
  GPAs 
  In 85.9  %   (893  /  1,040) of cases, the patient reported starting GPA 
therapy. Reasons for not initiating GPA treatment (146 patients, 
1 case with data missing) were infrequent  /  low-intensity pain 
(64 [43.8  %  ]), fear of adverse events (24 [16.4  %  ]), taking diff  erent 
analgesics (19 [13.0  %  ]), not understanding the doctor  ’  s instruc-
tions (15 [10.3  %  ]), and taking too many  /  unnecessary pills (5 
[3.4 % ]).  Fift  een (10.3  %  ) did not provide an answer, and three 
patients (2.1  %  ) gave other reasons. 
  Of the patients who initiated GPA therapy, 48 (5.4  %  ) failed to 
take the drug at some point for a mean of 8.5  ±  25.9 days.   Table 2  
summarizes the reasons given by patients for not taking the pre-
scribed GPA at some point during treatment which were forgetful-
ness (47.4  %  ) and the absence of either rheumatic or abdominal 
symptoms (39.5  %  ). Overall, 84.1  %   took the drug for 80  %   or more 
of the days prescribed. 
  Of patients who reported initiating NSAID therapy, 9.3  %   did 
not take concomitant GPA therapy at any point. In 11  %   of cases 
(95 %   CI:  9.0    −    13.2 % ),  GPA  therapy  either  was  not  initiated,  or 
was taken        <       80  %   of the time. Only eight patients had short-term 
prescription  of  GPA  (    <    30  days)  together  with  longer  (    >    30  days) 
prescription of NSAIDs. 
  To assess the concordance between patients  ’   reported behav-
ior and actual behavior, participants were asked to count the pills 
remaining from the last prescription at the end of the interview. 
Concerning GPA prescriptions, in 338  /  1,040 (32.5  %  ) cases the 
pill count was not performed because the patient had not started 
therapy, or was unable to perform the count for other reasons. 
      Table 2  .       Main reasons reported by patients for not taking 
the prescribed NSAID or GPA at some point (any day) during 
treatment among those who started therapy 
        Reason for lack of compliance       Number (  %  )       95  %   CI   
        NSAIDs     N  =233 (100  %  )      
           Adverse event    32 (15.7  %  )   11.0  %  , 21.4  %   
             Not having enough rheumatic 
symptoms 
  60 (29.4  %  )   23.2  %  , 36.2  %   
             Taking a different drug, or the 
prescribed drug was not effective 
  19 (9.3  %  )   5.7  %  , 14.1  %   
           Forgetfulness   26 (12.2  %  )   8.5  %  , 18.1  %   
           Not getting a second prescription    64 (31.4  %  )   25.1  %  , 38.2  %   
           Other   3 (1.4  %  )   0.3  %  , 4.2  %   
           Missing   29     —   
        GPAs      N  =48 (100  %  )       
           Adverse event    3 (7.9  %  )   1.7  %  , 21.4  %   
           Infrequent  /  mild-intensity pain    15 (39.5  %  )   24.0  %  , 56.6  %   
             Taking a different drug, or the 
prescribed drug was not effective 
  1 (2.6  %  )   0.1  %  , 13.8  %   
           Forgetfulness   18 (47.4  %  )   31.0  %  , 64.2  %   
           Other   1 (2.1  %  )   0.1  %  , 13.8  %   
           Missing   10     —   
          CI, conﬁ  dence interval; GPA, gastroprotective agent; NSAIDs, non-steroidal anti-
inﬂ  ammatory drugs.     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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short-term NSAID treatment, and the presence of adverse events 
were associated with poor patient adherence to NSAID prescrip-
tion. Logistic regression analysis demonstrated that of all variables 
considered in the models, short-term prescription of GPA therapy 
and the presence of adverse events were independent determi-
nants for poor adherence to the prescribed GPA. Th  e presence 
of uncomplicated ulcer history, short-term NSAID prescription, 
frequent NSAID dosing, and the presence of adverse events were 
associated with poor adherence to the prescribed NSAID ( Tables 3 
and 4  ).  Th  e major determinants of poor adherence to either 
NSAID or GPA prescription were the development of adverse 
events, which in most of cases were GI adverse events (dyspepsia 
being the most common). 
  We conducted additional analysis with (i) age as a risk factor 
when        >       65 years, instead of 60 years; (ii) the presence of very high 
GI risk, as defi  ned by the guidelines of the American College of 
Gastroenterology (  3  ), and (iii) excluding history of dyspepsia as 
a risk factor. Neither the presence  /  absence of very high GI risk, 
nor the presence  /  absence of dyspepsia showed statistically signi-
fi  cant diff  erences in either NSAID or GPA adherence; however, 
patients with very high GI risk showed a trend for greater adher-
ence to GPAs and less adherence to NSAIDs. When compared 
with  patients      <    65  years  old,  those      >    65  years  of  age  were  associ-
ated with a trend (  P     =    0.07)  toward  higher  levels  of  adherence  to 
GPA, but not NSAID therapy (similarly to the results obtained by 
using 60 years of age as the cutoff   point). When this variable (  ≥  65 
vs.     <    65 years of age) was included in the logistic regression model, 
it was not independently associated with poor adherence to GPA 
(data not shown). In addition to short-term prescription of GPA 
therapy  and  the  presence  of  adverse  events,  being      <    65  years  was 
Among patients who counted the pills, there was agreement in 
94.7  %   of cases between the patients  ’   self-report and the actual 
count. Regarding NSAID prescriptions, 55  %   of patients did not 
perform the pill count; among those who did, agreement was 
present in 91  %   of cases. For both drug types, the highest disagree-
ment occurred in patients who reported adherence between 20 
and  80 %   (GPAs:  27 / 38,  71 % ;  NSAIDs:  8 / 30,  26.7 % ).   
  Adverse events 
 Th  e frequency of adverse events was higher in patients who 
reported not optimal adherence to either GPA or NSAID pre-
scriptions; 22.1 %  (35 / 158) of patients with low adherence (    <    80 % ) 
to GPA had an adverse event, compared with 1.9  %   (16  /  838) of 
patients who were optimally adherent (  P     <    0.0001).  Similarly, 
17.0  %   (32  /  188) of patients who were not optimally adherent to 
NSAIDs had an adverse event, compared with 1.6  %   (12  /  737) of 
optimally adherent patients (  P     <    0.0001).  Adverse  events  were 
GI (30 dyspepsia, 3 diarrhea, and 1 bleeding event) in most 
cases (34  /  49). Th  e remaining events were non-GI, including 
cardiovascular / renal  (hypertension,  edema  ( n     =    4),  allergic  reac-
tions (  n     =    2),  headache  ( n     =    1),  and  unspecifi  ed (  n     =    13)).   
  Multivariate analysis for adherence 
  Univariate analysis revealed that of all clinical variables consid-
ered, concomitant use of a non-aspirin antiplatelet drug, overall 
use of any antiplatelet drug, high-dose GPA (PPI), short-term 
GPA treatment, and the presence of adverse events were associ-
ated with poor patient adherence to GPA prescription, while 
history of uncomplicated peptic ulcer disease, use of a non-
aspirin antiplatelet drug, dosing regimen for NSAID treatment, 
    Table 3  .       Factors associated with poor adherence to NSAID treatment 
        Variable      a              N   (  %  )   
    Crude odds ratio 
(95  %   CI)   
    Adjusted odds ratio 
(95  %   CI)      a     
      History of uncomplicated peptic ulcer    No   160 (85.1  %  ) 
         Yes   28 (14.9  %  )   1.8 (1.1, 2.9)    2.3 (1.4, 3.9) 
      Non-aspirin antiplatelet treatment    Yes   1 (0.5  %  ) 
         No   187 (99.5  %  )   6.8 (0.9, 50.7)      —   
      Antiplatelet treatment    Yes   14 (7.5  %  ) 
         No   174 (92.5  %  )   1.6 (0.9, 2.8)      —   
      Number of pills  /  day   Once daily    39 (20.7  %  ) 
         More than once daily    149 (79.3  %  )   1.6 (1.1, 2.3)    1.6 (1.1, 2.5) 
      Length of prescription          >      4 weeks    32 (17.8  %  ) 
           ≤      4 weeks    148 (82.2  %  )   2.4 (1.6, 3.6)    2.7 (1.7, 4.2) 
      Adverse events    No   156 (83.0  %  ) 
         Yes   32 (17.0  %  )   12.4 (6.2, 24.6)    14.9 (7.1, 31.2) 
          CI, conﬁ  dence interval; NSAIDs, non-steroidal anti-inﬂ  ammatory drugs; OR, odds ratio.     
      a        Adjusted ORs in the ﬁ  nal model.     
          ORs of variables that were not statistically signiﬁ  cant in the logistic regression model are not reported.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | MAY 2012   www.amjgastro.com
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independently associated with poor GPA adherence (odds ratio: 
2.2; 95  %   CI: 1.3       −       3.9) if the analysis was restricted to patients who 
reported initiating the prescribed NSAID therapy.       
  DISCUSSION 
 Th   is study focuses on patients  ’   adherence to both NSAIDs and 
GPAs. Previous studies showed low rates of GPA prescription to 
at-risk patients receiving NSAIDs, and low levels of adherence 
to GPA prescriptions among those who did receive co-therapy 
(  9  ), which was in turn associated with the increased risk of GI 
complications (  10,11  ). However, these studies did not investi-
gate the reasons for poor adherence or the determinants of poor 
adherence with regard to GPAs or NSAIDs. We believe that these 
aspects are of paramount importance because they are probably 
linked. Here, we have investigated these features by examining 
adherence to both GPA and NSAID therapies using a diff  erent 
approach, which is based on the direct questioning of patients 
concerning their reasons for not taking the prescribed medica-
tion. Consequently, we were able to discriminate and report on 
two aspects of the same spectrum: (i) failure to initiate the pre-
scribed treatment and (ii) lack of adherence to the prescribed 
drugs. 
  Rates of adherence to both therapies were high; however, con-
trary to what may be expected the proportion of patients who 
did not initiate the prescribed GPA therapy was higher than the 
proportion that did not initiate NSAID therapy. Th  is pattern 
may be due to the fact that patients who start NSAID therapy 
because they seek rheumatic pain relief do not necessarily expe-
rience GI symptoms, and some patients may not be aware of 
the increased GI risk associated with NSAID use. Interestingly, 
among patients who did not initiate NSAID therapy, failure to 
properly understand their doctor  ’  s instructions was most oft  en 
cited as the primary reason, suggesting that this aspect should 
be taken into consideration during the prescription process. On 
the contrary, among those who did not initiate GPA therapy, 
most patients did not do so because they had no (or mild) GI 
symptoms. Among patients who actually started therapy, a high 
proportion reported optimal drug adherence (defi  ned as taking 
the  prescribed  drug      >    80 %   of  the  days  prescribed)  for  both 
NSAIDs and GPAs; this proportion was actually higher than 
reported in other studies (  9  –  11  ), but is in agreement with the 
increasing trend of concomitantly prescribing a GPA to NSAID 
users (  20  ). Our diff  erent methodological approach may explain 
the fi  ndings of higher adherence rates. 
  Patients may falsely report high compliance levels because they 
have a false perception of compliance. We have tried to evalu-
ate this possibility by asking patients to report on the number of 
NSAID and GPA pills remaining at the time of the follow-up inter-
view. We could not obtain that information from all patients; how-
ever, among those who could actually count the pills, we found a 
high degree of agreement between the reported adherence and the 
number of pills taken from the prescribed boxes for both GPAs 
and NSAIDs. 
  Table 4  .       Factors associated with poor adherence to GPA treatment 
        Variable      a         Crude   %           N   (  %  )   
    Crude odds ratio 
(95  %   CI)   
    Adjusted odds ratio 
(95  %   CI)      a     
      Age (years)      ≥      60   72 (45.6  %  )          —     
               <      60   86 (54.4  %  )   1.3 (0.9, 1.8)     
      History of complicated peptic ulcer    Yes   2 (1.3  %  )          —     
         No   156 (98.7  %  )    
      Non-aspirin antiplatelet treatment    Yes   1 (0.6  %  )   2.9 (0.7, 12.2)        —     
         No   157 (99.4  %  )        
      Antiplatelet treatment    Yes   9 (5.7  %  )   5.8 (0.8, 43.0)        —     
         No   149 (94.3  %  )    
      Dose of gastroprotectant    Low   2 (1.3  %  )   2.1 (1.1, 4.3)        —     
         Standard   93 (59.6  %  )   0.9 (0.2, 4.5)     
         High   61 (39.1  %  )   1.9 (0.4, 8.5)     
      Length of prescription          >      4 weeks    34 (21.8  %  )    
           ≤      4 weeks    122 (78.2  %  )   2.3 (1.5, 3.5)    2.4 (1.6, 3.7) 
      Adverse events    No   123 (77.9  %  )    
         Yes   35 (22.1  %  )   14.6 (7.9, 27.2)    15.5 (8.2, 29.3) 
          CI, conﬁ  dence interval; GPA, gastroprotective agent; OR, odds ratio.     
      a        Adjusted ORs in the ﬁ  nal model.     
          ORs of variables that were not statistically signiﬁ  cant in the logistic regression model are not reported.     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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lower than-recommended doses, in clear contrast with the type of 
treatment and dosing prescribed for similar indications in rand-
omized controlled trials (  22,23  ). However, the doses of GPA pre-
scribed were either standard or high. Th  is prescription pattern 
may be guided by the perceived GI risk with NSAID treatment in 
an attempt to minimize adverse events, given that dose and dura-
tion are two factors linked to increased risk of upper GI complica-
tions  ( 2 ). 
  Our study has several strengths and limitations. Th  is study 
evaluated a real clinical sample, and direct contact with patients 
allowed us to take a diff  erent approach to evaluate the patient-
reported reasons for non-adherence, a factor that studies based 
on the data extracted from database platforms cannot report. Th  is 
study is limited by the lack of a direct, objective measure of pre-
scription use. Instead, we had to rely on the patients  ’   self-report-
ing, which may introduce recall bias. We have tried to limit the 
impact of recall bias by having patients report the number of pills 
remaining in their prescriptions. Among patients who were able 
to provide this information, we found a high level of agreement, 
which supports the validity of our study. In any case, it must also 
be recognized that having issued a prescription does not mean 
that patients will take the medication, an aspect that cannot be 
controlled in database studies. Another limitation is that our 
study reports mostly on short-term NSAID and GPA therapy, 
which we found to be the most frequent type of prescription in 
clinical practice. We did not evaluate the long-term use of these 
drugs, which might have provided diff  erent results. Th  e  fact  that 
most patients received short-term prescriptions justifi  ed the early 
telephone call to interview patients about adherence, because a 
later call might have had a negative impact on the accuracy of our 
data. It is possible that the study design induced a selection bias 
for patients who were prescribed short-term and not long-term 
treatment. 
  In summary, this study investigated the type of prescription, 
rate of adherence, and reasons for non-adherence to NSAID and 
GPA therapy in patients at increased risk of developing GI-related 
adverse events. NSAIDs and GPAs were prescribed short term in 
most cases. More subjects initiated NSAID than GPA therapy. We 
report high levels of adherence to both NSAID and GPA therapies, 
which supports recent data suggesting an important time trend 
decrease in the rate of upper GI complications in our country (  24  ). 
Still, there were more side eff  ects among patients with non-optimal 
adherence to GPA. Not understanding the doctor  ’  s instructions 
regarding drug use, infrequent  /  mild-intensity pain, and forgetful-
ness were the most frequently cited reasons for non-adherence. 
Adverse events and short-term treatment were the main clinical 
predictors of poor adherence for both NSAIDs and GPAs. His-
tory of peptic ulcer and frequent dosing were additional factors for 
poor NSAID adherence. We believe that these fi  ndings are relevant 
to attempts to improve adherence to both GPA and NSAID pre-
scriptions among at-risk patients.           
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  Among patients reporting poor adherence to medication, there 
was a higher level of adherence to GPA than to NSAID therapy; 
the reasons for poor adherence were diff  erent for the two drug 
types. Although the main reasons given for stopping NSAID 
therapy were infrequent  /  low-intensity rheumatic pain or devel-
oping adverse events, the main reason for stopping GPA therapy 
was forgetfulness, followed by the absence of either rheumatic or 
abdominal symptoms. If we consider that some of the reasons 
given (e.g., not getting a second prescription) may also refl  ect 
infrequent  /  low-intensity rheumatic pain, then this was the most 
oft   en-cited reason for non-adherence to prescribed NSAIDs. 
Th  ese fi  ndings reveal the primary underlying reasons driving 
drug use behavior in clinical practice, demonstrating that a sub-
stantial number of patients with chronic musculoskeletal condi-
tions take their NSAID prescription irregularly depending on the 
level of pain. Th   ese results also document that the development 
of adverse events (especially GI-related adverse events) is another 
major factor aff  ecting drug use. On the contrary, the main reason 
for not taking the GPA is probably linked to lack of GI symptoms 
in most cases. 
 Th  e development of adverse events is a well-known charac-
teristic of NSAID therapy. Th   e design and size of this study did 
not allow us to detect GI complications or determine whether 
poor adherence was associated with this serious adverse event. 
However, we were able to evaluate other patient-reported minor 
adverse events, which oft  en are not recorded in databases, but are 
suspected to be the main reasons for stopping NSAID use (  2  ). It 
should be noted that dyspepsia was the most commonly reported 
adverse event, and that patients who were non-adherent to GPA 
therapy had a signifi  cantly higher risk of this type of adverse 
event. 
 Th  is study also investigated clinical determinants of poor 
adherence to either NSAID or GPA prescriptions. History of pep-
tic ulcer disease and the presence of adverse events were predic-
tors of poor adherence to NSAID prescriptions and seem related 
to the well-known GI risk associated with NSAIDs. Concomitant 
use of a non-aspirin antiplatelet agent was also associated with 
poor adherence to GPA prescriptions, and may be related to the 
current warning from regulatory agencies to take PPIs together 
with clopidogrel (  21  ), although eventually this did not emerge as 
an independent factor. Frequent dosing (more than once daily) 
was a predictor of poor adherence to NSAID but not GPA pre-
scriptions, which may be due to the fact that PPIs are taken once 
daily, while NSAIDs are taken several times per day. Short-term 
treatment  (    <    30  days)  was  a  predictor  of  poor  adherence  for 
both therapies. Th   e reason for this is unclear, because short-term 
NSAID treatment was the most frequent prescription type in our 
study. It is possible that patients who received longer periods of 
therapy suff  ered from more severe musculoskeletal diseases and 
pain, which would increase adherence during the relatively short 
period of observation (15 and 60 days); however, this characteris-
tic was not recorded in our study. 
 Th   is study has also evaluated the prescription characteristics of 
both NSAIDs and GPAs in patients who are at risk for GI com-
plications. NSAID prescriptions were usually short-term and at The American Journal of GASTROENTEROLOGY  VOLUME 107 | MAY 2012   www.amjgastro.com
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 Study  Highlights 
    WHAT IS CURRENT KNOWLEDGE   
   3  Patients with gastrointestinal (GI) risk factors who require 
non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) need preven-
tion therapies to reduce the risk of serious GI complications. 
   3  Several studies have shown that these at-risk patients 
have low prescription rates of prevention therapy, and that 
patients have poor adherence to gastroprotectants. 
   3  Poor adherence to gastroprotective therapy in patients 
who are prescribed NSAIDs has been associated with and 
increased risk of upper GI bleeding. 
    WHAT IS NEW HERE   
   3  Low-dose, short-term non-steroidal anti-inﬂ  ammatory drug 
(NSAID) therapy is the most commonly issued prescription 
pattern for at-risk gastrointestinal (GI) patients in clinical 
practice in Spain. 
   3  A substantial number of patients co-prescribed with 
NSAIDs and a proton pump inhibitor (PPI) do not start 
gastro  protective therapy; however, 79.7 and 84.1  %   of 
patients reported optimal adherence to either NSAID or PPI 
therapy, respectively. 
   3  Infrequent  /  mild pain and forgetfulness were the most 
frequent reasons cited for non-adherence to NSAIDs or 
gastroprotectants. 
   3  Adverse events and short-term treatment were the main 
predictors of poor adherence for both NSAIDs and gastro-
protectants. History of peptic ulcer and frequent dosing 
were additional factors associated with non-adherence to 
NSAIDs. There were more adverse events among patients 
with non-optimal adherence to gastroprotectants than 
among patients with good adherence.                  
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